We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Genetic Mutation Linked to New Form of Diabetes

By LabMedica International staff writers
Posted on 02 Nov 2017
Finding the genetic cause of rare familial diabetes (monogenic diabetes) provides new biological insights into human pancreas development and function, as well as potentially novel therapeutic targets with important treatment implications.

Maturity-onset diabetes of the young (MODY) is a type of monogenic diabetes that develops as a result of beta-cell dysfunction and generally presents itself in affected patients before they are 25 years old. More...
Individuals with MODY also tend to be non-obese, non-insulin-dependent and have an autosomal dominant inheritance of diabetes.

An international team of scientists working with those at the University of Exeter Medical School, (Exeter, UK) studied different cohorts comprised of a discovery cohort comprises 38 European probands with strong MODY-like phenotype who did not have mutations in the three most common MODY genes; a replication cohort was derived from 469 non-Finnish European routine MODY diagnostic referrals; a Finnish-European replication MODY cohort, that consisted of 80 patients who were routinely referred for MODY diagnostic testing; and two other cohorts.

Plasma glucose was analyzed using the Hemocue Glucose System. Serum insulin was measured by an AutoDelfia fluoroimmunometric assay and serum C-peptide by Cobas e411 electrochemiluminometric immunoanalysis. Serum gastric inhibitory polypeptide (GIP) was analyzed using Millipore’s Human GIP Total ELISA. They sequenced MODY cases with unknown etiology and compared variant frequencies to large public databases. Amplicons were sequenced and reactions were analyzed on an ABI 3730 Capillary sequencer.

The investigators found that from 36 European patients, they identify two probands with novel Regulatory Factor X6 (RFX6) heterozygous nonsense variants. RFX6 protein truncating variants are enriched in the MODY discovery cohort compared to the European control population. They found similar results in 348 non-Finnish Europeans and 80 Finnish replication cohorts. RFX6 heterozygotes have reduced penetrance of diabetes compared to common MODY mutations. The hyperglycemia results from beta-cell dysfunction and is associated with lower fasting and stimulated gastric inhibitory polypeptide (GIP) levels. Of 27 patients who expressed RFX6-MODY, 81% were female and most patients were around 32 years old at the time of diagnosis.

Michael L. Weedon, PhD, the lead author of the study, said, “There has been limited recent success in finding new MODY genes. The reason for this limited success is the difficulty of distinguishing monogenic diabetes patients from those with type 1 diabetes, or from the increasing number of patients with early-onset type 2 diabetes due to rising rates of obesity.” The study was published on October 12, 2017, in the journal Nature Communications.

Related Links:
University of Exeter Medical School


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Quality Control Material
Multichem ID-B
New
Modular Hemostasis Automation Solution
CN Track
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.